These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15553066)

  • 21. Treatment of hepatitis C.
    Heathcote J; Main J
    J Viral Hepat; 2005 May; 12(3):223-35. PubMed ID: 15850462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment of chronic hepatitis C].
    Fehér J; Lengyel G
    Orv Hetil; 2004 May; 145(20):1065-7. PubMed ID: 15202329
    [No Abstract]   [Full Text] [Related]  

  • 25. Peginterferon and ribavirin for hepatitis C.
    Duggan AE; Duggan JM
    N Engl J Med; 2007 Mar; 356(12):1269; author reply 1271. PubMed ID: 17377169
    [No Abstract]   [Full Text] [Related]  

  • 26. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
    Wedemeyer H; Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
    [No Abstract]   [Full Text] [Related]  

  • 27. [Interferons alpha in the treatment of chronic HCV infections].
    Halota W; Pawłowska M; Andrejczyn M
    Przegl Epidemiol; 2004; 58(3):405-11. PubMed ID: 15730004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
    Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
    Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
    [No Abstract]   [Full Text] [Related]  

  • 30. A step forward in therapy for hepatitis C.
    Hoofnagle JH
    N Engl J Med; 2009 Apr; 360(18):1899-901. PubMed ID: 19403908
    [No Abstract]   [Full Text] [Related]  

  • 31. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 32. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of chronic hepatitis C in southern Taiwan.
    Chuang WL; Yu ML; Dai CY; Chang WY
    Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
    Pockros P; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Chan A; Hill G
    Hepatology; 2008 Oct; 48(4):1349-50. PubMed ID: 18821613
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of acute hepatitis C with PEG-interferon and ribavirin].
    Nicolas I; Pons JA
    Gastroenterol Hepatol; 2003 Apr; 26(4):275-6. PubMed ID: 12681125
    [No Abstract]   [Full Text] [Related]  

  • 36. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
    Jiménez-Méndez R; Castañeda-Hernández G
    Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PEG-IFN, RBV dosing during chronic HCV re-treatment.
    Highleyman L
    IAPAC Mon; 2007 Feb; 13(2):55. PubMed ID: 17948601
    [No Abstract]   [Full Text] [Related]  

  • 38. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
    Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D
    Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of chronic hepatitis C in haemodialysis patients requires more ribavirin.
    Slavenburg S; Drenth JP
    Nephrol Dial Transplant; 2008 Jul; 23(7):2430; author reply 2430-1. PubMed ID: 18400821
    [No Abstract]   [Full Text] [Related]  

  • 40. Mild hepatitis C: treat or monitor.
    Main J; Thomas H
    J Viral Hepat; 2006 May; 13(5):289. PubMed ID: 16637857
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.